Fibroblast Growth Factor Receptor 4 Gly388Arg Gene Polymorphism and Non-Hodgkin Lymphoma Susceptibility and Prognosis in Egyptian population: Case–control Study

Wafaa M. Abdelghany; Shahira Kamal Anis Botros; Osman Mohamed Mansour; Mahmoud A. Ayoub; Abdallah M. Almuslimani; Naglaa M. Hassan

doi:10.3889/oamjms.2021.5023

Authors

Wafaa M. Abdelghany Department of Clinical and Chemical Pathology
Shahira Kamal Anis Botros Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
Osman Mohamed Mansour Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
Mahmoud A. Ayoub Department of Clinical and Chemical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt
Abdallah M. Almuslimani Department of Clinical and Chemical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt
Naglaa M. Hassan Department of Clinical and Chemical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt

DOI:

https://doi.org/10.3889/oamjms.2021.5023

Keywords:

FGFR4, NHL, susceptibility, prognosis

Abstract

BACKGROUND: Angiogenesis is a multistep process having an essential role in the growth and progression of various tumors including hematolymphoid malignancies. Basic fibroblast growth factor (bFGF) is one of angiogenic growth factors which level is considered as prognostic factor in lymphoma and leukemia. It mediates its action by binding to high affinity cell surface receptors-fibroblast growth factor receptor 1–4 (FGFR4) with receptor kinase activity. Therefore, upregulation of BFGF-FGFR system may cause increased risk of non-Hodgkin lymphomas (NHLs).

AIM: Our study aimed to determine the association between the FGFR4 Gly388Arg (rs351855G/A) polymorphism and NHL disease susceptibility and prognosis.

MATERIALS AND METHODS: The present study included 75 NHL patients and 100 healthy controls. Genotyping of FGFR4 was done by Polymerase Chain Reaction-Restriction Fragment Length polymorphism (PCR-RFLP). As after the amplification of the target gene, the PCR products were digested with BstNI restriction endonuclease enzyme.

RESULTS: Analysis of FGFR4 Gly388Arg polymorphism revealed that the frequency of heterozygous (GA) mutation as well as the mutant allele (A) was significantly higher in cases compared to control subjects with p < 0.001 and 0.002, respectively. The mutant genotypes were more prevalent at older age, aggressive clinical stage, bone marrow involvement, anemia, and thrombocytopenia at presentation. The mean of overall survival and the event free survival of our NHL patients were shorter in the mutant genotypes with p = 0.049 and 0.017, respectively.

CONCLUSION: This study provides evidence that FGFR4 Gly388Arg polymorphism confers a genetic susceptibility to NHL among Egyptians and has a poor prognostic impact.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed., Vol. 2. Geneva, Switzerland: World Health Organization; 2017. p. 585.

Siegel R, Miller K, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. PMid:30620402 DOI: https://doi.org/10.3322/caac.21551

Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604-16. https://doi.org/10.1002/ajh.25460 PMid:30859597 DOI: https://doi.org/10.1002/ajh.25460

Freedman A. Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol. 2018;93(2):296-305. https://doi.org/10.1002/ajh.24937 PMid:29314206 DOI: https://doi.org/10.1002/ajh.24937

Clinical Practice Guidelines in Oncology. Chronic lymphocytic leukemia/small lymphocytic lymphoma. J Natl Compr Canc Netw. 2015;13(3):326-62. PMid:25736010

MirandaFilho A, Pineros M, Znaor A, MarcosGragera R, SteliarovaFoucher E, Bray F. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control 2019;30(5):10091. https://doi.org/10.1007/s10552-019-01155-5 DOI: https://doi.org/10.1007/s10552-019-01155-5

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries: Global cancer statistics. CA Cancer J Clin. 2018; 68(6): 394-424. https://doi.org/10.3322/caac.21492 DOI: https://doi.org/10.3322/caac.21492

Elsammak A. Clinical usefulness of PET-CT in staging, evaluation of treatment response and restaging of thoracic lymphoma. Egypt J Radiol Nuclear Med. 2017;48(4):1073-81. https://doi.org/10.1016/j.ejrnm.2017.04.005 DOI: https://doi.org/10.1016/j.ejrnm.2017.04.005

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-53. https://doi.org/10.1002/ijc.31937 PMid:30350310 DOI: https://doi.org/10.1002/ijc.31937

Cheng S, Li J, Liu W, Liu Ch, Su L, Liu X, et al. LTA + 252A > G polymorphism is associated with risk of nasal NK/T -cell lymphoma in a Chinese population: A case-control study. BMC Cancer. 2015;15:480. https://doi.org/10.1186/ s12885-015-1506-4 DOI: https://doi.org/10.1186/s12885-015-1506-4

Gao L, Feng Z, Li Q, Li L, Chen L, Xiao T. Fibroblast growth factor receptor 4 polymorphism is associated with increased risk and poor prognosis of non-Hodgkin’s lymphoma. Tumor Biol. 2014;35(4):2997-3002. https://doi.org/10.1007/s13277-013-1386-7 PMid:24248544 DOI: https://doi.org/10.1007/s13277-013-1386-7

Hallinan N, Finn S, Cuffe S, Rafee S, O’Byrne K, Gately K. Targeting the fibroblast growth factor receptor family in cancer. Cancer Treat Rev. 2016;46:51-62. https://doi.org/10.1016/j.ctrv.2016.03.015 PMid:27109926 DOI: https://doi.org/10.1016/j.ctrv.2016.03.015

Chen J, Hao P, Zheng T, Zhang Y. miR-628 reduces prostate cancer proliferation and invasion via the FGFR2 signaling pathway. Exp Ther Med. 2019;18(2):1005-12. https://doi.org/10.3892/etm.2019.7682 PMid:31316598 DOI: https://doi.org/10.3892/etm.2019.7682

Kang X, Lin Z, Xu M, Pan J, Wang Z. Deciphering role of FGFR signalling pathway in pancreatic cancer. Cell Prolif. 2019;52(3):e12605. https://doi.org/10.1111/cpr.12605 PMid:30945363 DOI: https://doi.org/10.1111/cpr.12605

Ou L, He X, Liu N, Song Y, Li J, Gao L, et al. Sialylation of FGFR1 by ST6Gal-I overexpression contributes to ovarian cancer cell migration and chemoresistance. Mol Med Report. 2020;21(3):1449-60. https://doi.org/10.3892/mmr.2020.10951 PMid:32016470 DOI: https://doi.org/10.3892/mmr.2020.10951

Xiong SW, Ma J, Feng F, Fu W, Shu SR, Ma T, et al. Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis. Oncotarget. 2017;8(15):25300-9. https://doi.org/10.18632/oncotarget.15811 PMid:28445975 DOI: https://doi.org/10.18632/oncotarget.15811

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non- Hodgkin lymphoma: The Lugano classification. J Clin Oncol. 2014;32(27):3059-68. https://doi.org/10.1200/jco.2013.54.8800 PMid:25113753 DOI: https://doi.org/10.1200/JCO.2013.54.8800

Mei Hsien CC, Wan Azman WA, Yusof M, Ho GF, Krupat E. Discrepancy in patient-rated and oncologist-rated performance status on depression and anxiety in cancer: A prospective study protocol. BMJ Open. 2012;2(5):e001799. https://doi.org/10.1136/bmjopen-2012-001799 PMid:23035016 DOI: https://doi.org/10.1136/bmjopen-2012-001799

Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, et al. Does the presence of tumor-induced cortical bone destruction at CT have any prognostic value in newly diagnosed diffuse large B-cell lymphoma? Skeletal Radiol. 2015;44(5):687-94. https://doi.org/10.1007/s00256-015-2102-z PMid:25662178 DOI: https://doi.org/10.1007/s00256-015-2102-z

Treating Non Hodgkin lymphoma-American cancer society. cancer.org | 1.800.227.2345. 2018; P1-49. Available from: https://www.cancer.org/content/dam/CRC/PDF/Public/8720.00. pdf.

Wróbel T, Mazur G, Dzietczenia J, Gębura K, Kuliczkowski K, Bogunia-Kubik K. VEGF and bFGF gene polymorphisms in patients with non-Hodgkin’s lymphoma. Biomed Res Int. 2013;2013:59813. https://doi.org/10.1155/2013/159813 PMid:23998120 DOI: https://doi.org/10.1155/2013/159813

Cha Z, Zang Y, Guo H, Gu H, Tu X, Song H, et al. Fibroblast growth factor receptor 4 polymorphisms and the prognosis of non-Hodgkin lymphoma. Mol Biol Rep. 2014;41(2):1165-70. https://doi.org/10.1007/s11033-013-2963-y PMid:24381107 DOI: https://doi.org/10.1007/s11033-013-2963-y

Tang S, Hao Y, Yuan Y, Liu R, Chen Q. Role of fibroblast growth factor receptor 4 in cancer. Cancer Sci. 2018;109(10):3024-31. https://doi.org/10.1111/cas.13759 PMid:30070748 DOI: https://doi.org/10.1111/cas.13759

Ulaganathan VK, Ullrich A. Membrane-proximal binding of STAT3 revealed by cancer-associated receptor variants. Mol Cell Oncol. 2016;3(3):e1145176. https://doi.org/10.1080/23723 556.2016.1145176 PMid:27314095 DOI: https://doi.org/10.1080/23723556.2016.1145176

Tateno T, Asa SL, Zheng L, Mayr T, Ullrich A, Ezzat S. The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis. PLoS Genet. 2011;7(12):e1002400. https://doi.org/10.1371/journal.pgen.1002400 PMid:22174695 DOI: https://doi.org/10.1371/journal.pgen.1002400

Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U, et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol. 2005;23(29):7307-11. https://doi.org/10.1200/ jco.2005.17.350 PMid:16061909 DOI: https://doi.org/10.1200/JCO.2005.17.350

Chou CH, Hsieh MJ, Chuang CY, Lin JT, Yeh CM, Tseng PY, et al. Functional FGFR4 Gly388Arg polymorphism contributes to oral squamous cell carcinoma susceptibility. Oncotarget. 2017;8(56):96225-38. https://doi.org/10.18632/oncotarget.21958 PMid:29221201 DOI: https://doi.org/10.18632/oncotarget.21958